

**FOR IMMEDIATE RELEASE**

May 15, 2024

Listed Company Name:	Eisai Co., Ltd. Haruo Naito
Representative:	Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange Sayoko Sasaki
Inquiries:	Vice President, Corporate Communications Phone +81-3-3817-5120

**Notice Concerning Appointment of New Representative Officer**

Eisai Co., Ltd. (“the Company”) resolved at its Board of Directors meeting held on May 15, 2024, to appoint a new Representative Corporate Officer, effective June 14, 2024 as described below.

1. Reason for Change

The Company is dedicated to maximizing our contribution to global patients and building a dementia ecosystem through our efforts with the Alzheimer’s Disease treatment LEQEMBI. To realize our Corporate Concept and achieve sustainable growth, the corporate officer responsible for leading the maximization of corporate value based on this strategy will be assigned as a representative corporate officer.

2. Appointment of New Representative Corporate Officer (effective June 14, 2024)

(Newly Appointed Representative Corporate Officer)

New Job Title	Name	Current Job Title
Representative Corporate Officer and Executive Vice President	Keisuke Naito	Senior Vice President Chief Strategy and Planning Officer Chief Ecosystem Officer Global Alzheimer’s Disease Officer

### 3. Career Summary of Newly Appointed Representative Corporate Officer

Name: Keisuke Naito

Date of Birth: August 18, 1988

October 2013	Joined the Company
February 2019	Head of Dementia Total Inclusive Ecosystem HQs
June 2019	Vice President
June 2019	Chief Digital Officer
June 2019	Assigned to Dementia Total Inclusive Ecosystem
January 2020	President, Dementia Total Inclusive Ecosystem HQs
October 2020	Head of Consumer Experience Transformation HQs
October 2020	Deputy President, Eisai Japan
June 2021	Chief Ecosystem Officer (Current)
April 2022	Head of Global IT Management HQs
June 2023	Senior Vice President (Current)
June 2023	Chief Strategy & Planning Officer (Current)
August 2023	Global Alzheimer's Disease Officer (Current)

Number of shares held: 970 shares (as of March 31, 2024)

### 4. Scheduled Transfer Date

June 14, 2024

\*\*\*